menu
FOR U.S. HEALTHCARE PROFESSIONALS
Akynzeo

Helsinn Cares AKYNZEO® Reimbursement and Access Support Resources


Patient Access Support for Healthcare Professionals

The Helsinn Cares program is designed to provide AKYNZEO® patient assistance and resources for AKYNZEO® reimbursement, and to help you and your office staff focus on patient care.

Enrollment Form Enrollment Form

Helsinn Cares Enrollment Form

Download Enrollment Form
Copay Card Copay Card

AKYNZEO® Co-pay Card

Learn About the Co-pay card
Billing and Coding Guide Billing and Coding Guide

AKYNZEO® Billing and Coding Guide

Download Guide

To help your patients with AKYNZEO® affordability, start the process by enrolling your patients in Helsinn Cares today!

When you enroll your patients in Helsinn Cares, the program can help with confirming benefit coverage and facilitate prior authorizations or appeals, when required. And, if your patient meets eligibility criteria, then he or she will be considered for the Patient Assistance Program, which provides AKYNZEO® savings for patients.

To enroll a patient in Helsinn Cares download the Enrollment Form or call 1‑84HELSINN‑U (1‑844‑357‑4668), select prompt 2.

AKYNZEO® Prescribing Information


AKYNZEO® Billing and Coding

HCPCS Level III Code
HCPCS Code
(J Code)
Description
J8655 Netupitant 300 mg and Palonosetron 0.5 mg, oral
When billing for certain drugs, payers require physicians to indicate on the claim form the quantity of product administered to the patient, expressed in the number of units described by the HCPCS code. Report 1 unit of J8655 for one AKYNZEO® capsule.
ICD-10-CM Diagnosis Codes
ICD-10-CM
Diagnosis Code
Description
R11.2 Nausea with vomiting, unspecified
R11.0 Nausea
R11.10 Vomiting, unspecified
R11.11 Vomiting without nausea
R11.12 Projectile vomiting
National Drug Codes (NDC)
AKYNZEO® Package Size NDC
Single-dose capsule: 300 mg netupitant/0.5 mg palonosetron 62856-796-01
Pack of four capsules (two capsules per blister strip): 300 mg netupitant/0.5 mg palonosetron 62856-796-04
Some payers require providers to report 11-digit NDCs when reporting a drug on a claim form. Converting the 10-digit NDC for AKYNZEO® to an 11-digit NDC requires the use of a leading zero in the product code section of the AKYNZEO® NDC (ie, the middle section).
ICD-10-CM Supplementary Classification Codes
ICD-10-CM Supplementary Classification Code Description
T45.1X5 Adverse effect of antineoplastic and immunosuppressive drugs
Z41.8 Encounter for other procedures for purposes other than remedying health state
Z51.11 Encounter for antineoplastic chemotherapy
Providers should use current ICD-10-CM diagnosis codes to report a patient’s diagnosis on claim submissions. Please check with the payer to verify coding or special billing requirements.
Billing and Coding Guide

<-Get the
complete AKYNZEO®
Billing
and Coding
Guide here. Download Guide


Helsinn Cares provides tools — for you and your
patients — to support reimbursement and access to AKYNZEO®.

Helsinn is committed to helping every patient obtain the Helsinn medication he or she needs. For answers to specific questions, please call 1‑84HELSINN‑U (1‑844‑357‑4668), select prompt 1 for medical information; select prompt 2 for Helsinn Cares.

 

Indication

AKYNZEO is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO is an oral fixed combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.1

Important Safety Information

Warnings and Precautions

 

Adverse Reactions

Drug Interactions

Use in Specific Populations

For more information about AKYNZEO, please see Full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Helsinn at 1‑84HELSINN‑U (1‑844‑357‑4668), select prompt 1 for medical information, or FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.

Reference:

1. AKYNZEO® (netupitant/palonosetron) capsules. Full Prescribing Information.

Expand

Indication

AKYNZEO is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO is an oral fixed combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.1

Important Safety Information

Warnings and Precautions

 

Adverse Reactions

Drug Interactions

Use in Specific Populations

For more information about AKYNZEO, please see Full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Helsinn at 1‑84HELSINN‑U (1‑844‑357‑4668), select prompt 1 for medical information, or FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.

Reference:

1. AKYNZEO® (netupitant/palonosetron) capsules. Full Prescribing Information.

Indication

AKYNZEO is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO is an oral fixed combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.1